CJC-1295 (DAC) Research Evidence
The CJC-1295 (DAC) evidence base: trials, journals, and what the data does not yet show.
Key Findings at a Glance
• The Drug Affinity Complex modification allows CJC-1295 to covalently bond to serum albumin after injection, extending its half-life from minutes to 6 to 8 days. • A single injection of CJC-1295 with DAC can elevate IGF-1 levels for up to two weeks, a duration unmatched by any other GHRH analog studied in clinical settings. • CJC-1295 combined with a GHRP such as Ipamorelin or GHRP-6 produces 2 to 5 times more growth hormone than either peptide alone, due to activation of complementary pituitary pathways. • CJC-1295 exists in two distinct forms with vastly different pharmacokinetics: the DAC version acts for days, while Modified GRF 1-29 without DAC has a half-life of only 30 minutes.
Body Composition Research
Research indicates CJC-1295 may influence body composition through multiple GH and IGF-1 mediated pathways including enhanced lipolysis (fat breakdown), increased lean body mass, and improved protein synthesis in skeletal muscle tissue. Studies have documented potential reductions in visceral adipose tissue (abdominal fat), which is associated with metabolic disease risk, along with improvements in fat-free mass. The peptide has been investigated for obesity research applications, sarcopenia (age-related muscle loss) prevention studies, and metabolic syndrome investigations. Long-term animal studies suggest favorable body composition changes including reduced body fat percentage and increased muscle mass without the water retention sometimes associated with direct GH administration. These findings have implications for research into healthy aging, athletic performance optimization, and metabolic health.
Sleep Quality Studies
Preliminary research suggests CJC-1295 may improve sleep architecture, particularly enhancing slow-wave (deep) sleep phases when natural growth hormone release peaks occur. Studies indicate that optimized GH pulsatility achieved through GHRH analog administration may support the natural relationship between deep sleep and growth hormone secretion. Research has documented improvements in subjective sleep quality measures and potential enhancement of recovery processes associated with quality sleep. These findings have implications for aging research where both sleep quality and GH production naturally decline, as well as for recovery optimization studies in athletic and rehabilitation contexts. The sustained GH elevation may support overnight recovery and tissue repair processes.
Trials and reviews
- Teichman Phase I dose-escalationJCEM2006
GH 2-10x and IGF-1 1.5-3x for 6-8 days after one dose · N=66
References
- Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 · Teichman SL, et al. · 2006
- Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. · Hoffmann P, Feige JJ, Alfaidy N · 2006
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. · Sackmann-Sala L, Ding J, Frohman LA et al. · 2009
- Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005. · Chung S, Son GH, Park SH, Park E, Lee KH, Geum D, Kim K · 2005
- Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006. · Zaidi D, James KA, Wagner GF · 2006
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. · Ionescu M, Frohman LA · 2006
- Substances in Compounding that May Present Significant Safety Risks
- Ionescu M, Bhopale G. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog. Growth Hormone & IGF Research. 2009. · Nummenmaa L, Calder AJ · 2009
- The study of doping market: How to produce intelligence from Internet forums. · Pineau T, Schopfer A, Grossrieder L et al. · 2016
- [PDF] December 4, 2024 Pharmacy Compounding Advisory Committee ... · 2024
- Thomas A, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2011. · Chiaretti A, Ruggiero A, Barbi E, Pierri F, Maurizi P, Fantacci C, Bersani G, Riccardi R · 2011